228 related articles for article (PubMed ID: 21448288)
21. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
22. Is the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma?
Güngördük K; Plett H; Gülseren V; Meydanlı M; Boyraz G; Özdemir İ; Şahin H; Şenol T; Yıldırım N; Turan T; Öge T; Gökçü M; Taşkın S; Ayhan A; Ataseven B
Oncol Res Treat; 2021; 44(1-2):43-51. PubMed ID: 33249415
[TBL] [Abstract][Full Text] [Related]
23. Rap1GAP inhibits tumor progression in endometrial cancer.
Tamate M; Tanaka R; Osogami H; Matsuura M; Satohisa S; Iwasaki M; Saito T
Biochem Biophys Res Commun; 2017 Apr; 485(2):476-483. PubMed ID: 28196746
[TBL] [Abstract][Full Text] [Related]
24. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
25. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
26. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
28. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
31. Hypomethylation-induced expression of S100A4 in endometrial carcinoma.
Xie R; Loose DS; Shipley GL; Xie S; Bassett RL; Broaddus RR
Mod Pathol; 2007 Oct; 20(10):1045-54. PubMed ID: 17673926
[TBL] [Abstract][Full Text] [Related]
32. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Saccharomyces cerevisiae -like 1 (SEC14L1) in Gynecologic Malignancies Shows Overexpression in Endometrial Serous Carcinoma.
Banet N; Masnick M; Quddus MR
Int J Gynecol Pathol; 2023 Mar; 42(2):136-142. PubMed ID: 35283446
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
Creasman WT; Kohler MF; Odicino F; Maisonneuve P; Boyle P
Gynecol Oncol; 2004 Dec; 95(3):593-6. PubMed ID: 15581969
[TBL] [Abstract][Full Text] [Related]
35. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
36. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; Haddock MG; Keeney GL; Long HJ; Dowdy SC; Podratz KC
Gynecol Oncol; 2013 Jun; 129(3):478-85. PubMed ID: 23535279
[TBL] [Abstract][Full Text] [Related]
37. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.
Mhawech-Fauceglia P; Herrmann RF; Kesterson J; Izevbaye I; Lele S; Odunsi K
Eur J Surg Oncol; 2010 Dec; 36(12):1195-201. PubMed ID: 20926229
[TBL] [Abstract][Full Text] [Related]
39. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
[TBL] [Abstract][Full Text] [Related]
40. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]